目的探讨术前新辅助放化疗在可切除食管癌治疗中的作用。
Objective To explore the effect of pre-operative adjuvant chemo-radiotherapy and surgical treatment on resectable esophageal cancer.
最近，新辅助放化疗的出现已经根本改变了限局型浸润型结肠癌患者的治疗方式。
More recently, the emergence of neo-adjuvant chemoradiotherapy has fundamentally changed the management of patients with locally advanced disease.
该研究对接受综合模式治疗的LRRC患者进行了评估，该模式包括新辅助放化疗、扩大切除术和术中放疗。
This study assessed the outcome of LRRC patients treated with multimodality treatment, consisting of neoadjuvant radio (chemo-) therapy, extended resection, and intraoperative radiotherapy.
目的：评估在局部进展期直肠癌患者中联合贝伐单抗和标准放化疗的新辅助治疗有效性和安全性，并探索标志物反应。
Purpose To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response.
结果扩大根治切除、新辅助放疗化疗、原位肝移植、光动力学治疗和分子放化疗均能有效地提高患者的生存率。
Results Extended radical resection, neoadjuvant chemotherapy, orthotopic liver transplantation, photodynamic therapy and molecular chemoradiotherapy might improve the survival rate.
结果扩大根治切除、新辅助放疗化疗、原位肝移植、光动力学治疗和分子放化疗均能有效地提高患者的生存率。
Results Extended radical resection, neoadjuvant chemotherapy, orthotopic liver transplantation, photodynamic therapy and molecular chemoradiotherapy might improve the survival rate.
应用推荐